Physician profile
Davide Iacobelli
NPI 1992783872
$240,097.07
in general payments reported to CMS, 2019-2025
20 companies · $707 in 2025
The $707 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168K · 2020: $58K · 2021: $14K · 2022: $123 · 2024: $566 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $70,321.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $62,057.17 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $56,286.86 | 2019-2021 | |
| Abbvie INC. | $19,900.60 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15,885.53 | 2019-2021 | |
| Celgene Corporation | $10,709.49 | 2019 | |
| Amgen INC. | $2,020.86 | 2019-2025 | Tavneos, Otezla, Enbrel |
| Ucb, INC. | $1,862.60 | 2019-2021 | |
| Janssen Biotech, INC. | $417.32 | 2019-2021 | |
| Genzyme Corporation | $290.75 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $161.69 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $74.33 | 2019-2021 | |
| Allergan, INC. | $27.31 | 2021 | |
| Mayne Pharma Commercial LLC | $18.57 | 2019 | |
| Genentech USA, INC. | $13.99 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $13.75 | 2019 | |
| Pfizer INC. | $13.52 | 2021 | |
| Strata Skin Sciences, INC. | $12.02 | 2021 | |
| Biofrontera INC. | $9.17 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davide Iacobelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.